Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:39:53 EDT Wed 17 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CHRS - COHERUS BIOSCIENCES INC - http://www.coherus.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CHRS - Q1.02.12·2.224.82.151,257.42,5374,0812.17  2.22  2.128.34  1.430118:11:36Apr 0815 min RT 2¢

Recent Trades - Last 10 of 4081
Time ETExPriceChangeVolume
18:11:36Q2.18990.039950
18:11:11Q2.18860.038650
16:38:59Q2.160.011,001
16:20:00Q2.15 254
16:17:14Q2.170.0210
16:17:14Q2.170.02190
16:16:22Q2.170.021
16:03:20Q2.200.05671
16:02:36Q2.200.051,000
16:02:13Q2.200.051,001

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-08 08:30U:CHRSNews ReleaseCoherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
2024-03-13 16:01U:CHRSNews ReleaseCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
2024-03-05 16:01U:CHRSNews ReleaseCoherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
2024-03-04 01:00U:CHRSNews ReleaseCoherus Completes Divestiture of Ophthalmology Franchise
2024-02-23 17:33U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2024-02-21 08:30U:CHRSNews ReleaseCoherus Announces U.S. Launch of UDENYCA ONBODY ¢ „ ¢ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2024-02-05 08:00U:CHRSNews ReleaseCoherus Amends Term Loan Agreement with Pharmakon Advisors, LP
2024-01-22 01:15U:CHRSNews ReleaseCoherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
2024-01-18 16:05U:CHRSNews ReleaseCoherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
2024-01-04 08:00U:CHRSNews ReleaseINOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI ¢ „ ¢ (toripalimab-tpzi)
2024-01-03 09:00U:CHRSNews ReleaseCoherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 08:29U:CHRSNews ReleaseCoherus Announces U.S. Launch of LOQTORZI ¢ „ ¢
2023-12-26 16:01U:CHRSNews ReleaseCoherus Announces FDA Approval of UDENYCA ONBODY ¢ „ ¢, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2023-12-22 17:00U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2023-12-11 08:30U:CHRSNews ReleaseCoherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
2023-12-07 17:56U:CHRSNews ReleaseCoherus BioSciences Announces CFO Transition Plans
2023-12-06 04:00U:CHRSNews ReleaseCoherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
2023-11-28 11:16U:CHRSNews ReleaseCoherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical As
2023-11-06 16:08U:CHRSNews ReleaseCoherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
2023-11-03 08:30U:CHRSNews ReleaseCoherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)